bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate and lg 100268

bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate has been researched along with lg 100268 in 1 studies

*LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source [MeSH]

Compound Research Comparison

Studies (bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate)	Trials (bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate)	Recent Studies (post-2010) (bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate)	Studies (lg 100268)	Trials (lg 100268)	Recent Studies (post-2010) (lg 100268)
40	1	2	108	0	28

Protein Interaction Comparison

Protein	Taxonomy	bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate (IC50)	lg 100268 (IC50)
Retinoic acid receptor RXR-alpha	Homo sapiens (human)		0.008

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, P; Kim, H; Krajewski, S; Labrie, F; Lamph, W; Liby, K; Rendi, M; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR; Xu, X	1

Other Studies

1 other study(ies) available for bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate and lg 100268

Article	Year
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19 Topics: Animals; Cell Division; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nicotinic Acids; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tetrahydronaphthalenes; Thiophenes	2006

Article

Year

The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

Topics: Animals; Cell Division; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nicotinic Acids; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tetrahydronaphthalenes; Thiophenes

2006